Nektar Therapeutics (NKTR) Stock Analysis and Metrics

Nektar Therapeutics

NASDAQ: NKTR

$70.78 ▲ +1.42 (+2.05%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.76 Bn

P/E-14.94

P/S31.63

Div. Yield0.00

Revenue Growth (1y) (Qtr)3.83

Add ratio to table…

About

Nektar Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative immunotherapies. The company focuses on creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve therapeutic outcomes in autoimmune diseases and oncology. Nektar applies its deep expertise in immunology to identify and advance drug candidates through preclinical and clinical development, with a pipeline centered on novel mechanisms to address unmet medical needs.

The company generates revenue primarily through collaboration agreements, royalties, and milestone payments from partnered drug programs. Historically, Nektar earned manufacturing revenue and product sales from its proprietary polyethylene glycol (PEG) reagents, though it sold its manufacturing facility in December 2024. Following the termination of its collaboration with Eli Lilly and Company for rezpegaldesleukin, Nektar no longer receives collaboration-based revenues for its lead drug candidates unless new partnerships are established. Royalties from previously partnered products, such as ADYNOVATE, MOVANTIK, and CIMZIA, continue to contribute to revenue.

The company operates through the following segments:

• Autoimmune Diseases: This segment focuses on developing therapies to restore immune balance in patients with autoimmune and inflammatory disorders. The lead candidate, rezpegaldesleukin, is a first-in-class resolution therapeutic designed to stimulate regulatory T cells (Tregs) by targeting the interleukin-2 (IL-2) receptor complex. Rezpegaldesleukin is being evaluated in Phase 2b trials for moderate-to-severe atopic dermatitis and severe-to-very-severe alopecia areata, with Fast Track designation granted by the FDA for both indications. Additional preclinical programs, NKTR-0165 and NKTR-0166, target the tumor necrosis factor receptor type II (TNFR2) pathway for autoimmune diseases like ulcerative colitis and multiple sclerosis.

• Oncology: This segment aims to activate the body’s natural tumor-fighting mechanisms through immune system modulation. The lead candidate, NKTR-255, is an investigational biologic targeting the interleukin-15 (IL-15) pathway to enhance natural killer (NK) cell and CD8+ memory T cell function. NKTR-255 is being evaluated in combination with cell therapies and checkpoint inhibitors in clinical collaborations with institutions such as Fred Hutchinson Cancer Center and Merck KGaA. The program is designed to sustain durable anti-tumor immune responses in cancers like large B-cell lymphoma and urothelial carcinoma.

• Preclinical and Discovery Programs: This segment includes early-stage research initiatives leveraging Nektar’s polymer conjugate technology and immunology expertise. Programs such as NKTR-422, a PEG-modified colony-stimulating factor 1 (CSF1) candidate, target inflammation and fibrosis. The company also explores novel drug candidates across proteins, peptides, and antibodies to expand its pipeline.

Nektar Therapeutics occupies a niche position within the biopharmaceutical industry, competing in the immunotherapy space with a focus on selective immune modulation. In autoimmune diseases, rezpegaldesleukin competes with cytokine-based, microbiome-based, and regulatory T cell therapies from companies like Regeneron, Eli Lilly, Sanofi, and AstraZeneca. In oncology, NKTR-255 faces competition from engineered IL-15 biologics and cell therapies developed by ImmunityBio, Nkarta, and Roche. The company’s competitive advantages include its proprietary polymer conjugate technology, which enhances drug pharmacokinetics and safety profiles, and its deep immunology expertise. However, Nektar operates in a highly competitive landscape with larger pharmaceutical companies possessing greater financial and commercial resources.

The company’s customer base primarily consists of pharmaceutical and biotechnology partners, healthcare providers, and patients. Historically, Nektar derived significant revenue from collaborations with partners such as Takeda Pharmaceuticals, AstraZeneca, UCB Pharma, and Pfizer, which commercialized products incorporating its PEGylation technology. Following the sale of its manufacturing facility, Nektar’s revenue streams shifted toward royalties and milestone payments. For its proprietary drug candidates, the company targets patients with autoimmune diseases and cancer, though commercialization will depend on regulatory approvals and potential future partnerships.

Investment Thesis

▲ Bull case

The company has shown that longer dosing with ResPEG not only maintains but deepens clinical response over time in atopic dermatitis with notable increases in complete skin clearance rates and improvement in comorbid asthma that current biologics do not address. This suggests a potential label claim for asthma control which could expand the addressable patient pool beyond skin disease alone. The durability observed with monthly and quarterly dosing indicates a regimen that could rival or exceed the convenience of existing therapies while offering a novel immune modulating mechanism. Such a differentiated profile could allow ResPEG to capture share from both biologic naive and experienced patients who are dissatisfied with current IL 13 blockers.
In alopecia areata the 52 week data demonstrated new SALT 20 responses in patients who had not responded earlier indicating a progressive hair regrowth effect that could support a label claim for long term use without the safety monitoring burdens of JAK inhibitors. The high completion rate in the extension period underscores patient willingness to stay on twice monthly dosing when they see tangible benefit. This positions ResPEG as a first line biologic with a favorable safety profile and a dosing schedule that may improve adherence relative to daily oral JAK inhibitors. The ability to treat severe to very severe disease with a biologic that avoids boxed warnings could unlock a large untreated population.
Financial strength is a hidden catalyst with over one billion dollars in cash after recent financings providing a runway that extends well beyond anticipated Phase 3 data readouts in 2028 and reduces dilution risk for near term investors. This cash buffer enables the company to pursue multiple indications in parallel including the ongoing type 1 diabetes trial with TrialNet and early stage TNFR2 programs without needing to seek additional financing in the near term. The balance sheet strength also supports potential strategic partnerships or acquisitions that could accelerate development timelines. Market participants may be underestimating the de risking effect of this liquidity cushion on the binary outcomes of Phase 3 trials.
The Treg mechanism of ResPEG acts upstream of cytokine pathways offering a potential advantage in diseases where downstream blockade has led to tachyphylaxis or safety concerns as seen with IL 13 blockers and JAK inhibitors. Early data from the type 1 diabetes study suggest a signal of C peptide preservation that if validated could open a large market in autoimmune endocrine disease. Expanding beyond the two lead indications could create a platform pipeline where each new indication adds incremental value and validates the core technology. This platform approach could transform the company from a single asset bet to a diversified biotech with multiple near term catalysts.
Management highlighted that the Phase 3 program in atopic dermatitis is designed with a biologic naive study and a separate biologic experienced study enabling direct comparison to incumbent therapies such as Dupixent and lebrikizumab which could facilitate a faster regulatory review if superiority or non inferiority is demonstrated. The inclusion of a treatment experienced cohort addresses a key unmet need for patients who have lost response to existing biologics a scenario that is growing as more patients achieve long term use of current agents. Success in this cohort could allow ResPEG to be positioned as a rescue therapy thereby capturing additional market share beyond the naive population. The regulatory pathway appears clarified with the FDA accepting single pivotal studies in similar indications which reduces the complexity and cost of the approval process.

The company has shown that longer dosing with ResPEG not only maintains but deepens clinical response over time in atopic dermatitis with notable increases in complete skin clearance rates and improvement in comorbid asthma that current biologics do not address. This suggests a potential label claim for asthma control which could expand the addressable patient pool beyond skin disease alone. The durability observed with monthly and quarterly dosing indicates a regimen that could rival or exceed the convenience of existing therapies while offering a novel immune modulating mechanism. Such a differentiated profile could allow ResPEG to capture share from both biologic naive and experienced patients who are dissatisfied with current IL 13 blockers.
In alopecia areata the 52 week data demonstrated new SALT 20 responses in patients who had not responded earlier indicating a progressive hair regrowth effect that could support a label claim for long term use without the safety monitoring burdens of JAK inhibitors. The high completion rate in the extension period underscores patient willingness to stay on twice monthly dosing when they see tangible benefit. This positions ResPEG as a first line biologic with a favorable safety profile and a dosing schedule that may improve adherence relative to daily oral JAK inhibitors. The ability to treat severe to very severe disease with a biologic that avoids boxed warnings could unlock a large untreated population.
Financial strength is a hidden catalyst with over one billion dollars in cash after recent financings providing a runway that extends well beyond anticipated Phase 3 data readouts in 2028 and reduces dilution risk for near term investors. This cash buffer enables the company to pursue multiple indications in parallel including the ongoing type 1 diabetes trial with TrialNet and early stage TNFR2 programs without needing to seek additional financing in the near term. The balance sheet strength also supports potential strategic partnerships or acquisitions that could accelerate development timelines. Market participants may be underestimating the de risking effect of this liquidity cushion on the binary outcomes of Phase 3 trials.
The Treg mechanism of ResPEG acts upstream of cytokine pathways offering a potential advantage in diseases where downstream blockade has led to tachyphylaxis or safety concerns as seen with IL 13 blockers and JAK inhibitors. Early data from the type 1 diabetes study suggest a signal of C peptide preservation that if validated could open a large market in autoimmune endocrine disease. Expanding beyond the two lead indications could create a platform pipeline where each new indication adds incremental value and validates the core technology. This platform approach could transform the company from a single asset bet to a diversified biotech with multiple near term catalysts.
Management highlighted that the Phase 3 program in atopic dermatitis is designed with a biologic naive study and a separate biologic experienced study enabling direct comparison to incumbent therapies such as Dupixent and lebrikizumab which could facilitate a faster regulatory review if superiority or non inferiority is demonstrated. The inclusion of a treatment experienced cohort addresses a key unmet need for patients who have lost response to existing biologics a scenario that is growing as more patients achieve long term use of current agents. Success in this cohort could allow ResPEG to be positioned as a rescue therapy thereby capturing additional market share beyond the naive population. The regulatory pathway appears clarified with the FDA accepting single pivotal studies in similar indications which reduces the complexity and cost of the approval process.

▼ Bear case

The Phase 3 trials are still pending initiation and historical data show that moving from Phase 2b to Phase 3 often reveals unexpected safety signals or diminished efficacy especially when scaling to larger and more diverse patient populations. The reliance on a novel mechanism means there is limited long term safety data beyond the current exposure which could raise concerns among regulators and payers regarding chronic use. Any adverse event signal in the larger trials could jeopardize the BLA timeline and increase the need for additional studies. Investors may be overlooking the execution risk inherent in advancing a first in class immunomodulator to pivotal trials.
Although the company emphasizes a differentiated safety profile the JAK inhibitor class already faces boxed warnings and the introduction of a new biologic does not guarantee avoidance of safety signals particularly as the drug modulates regulatory T cells which could theoretically lead to immune suppression or paradoxical autoimmunity. The asthma improvement signal while promising also introduces complexity because demonstrating a benefit in a comorbid condition may require additional trials and could expand the safety monitoring burden. The market may be assuming safety advantages without sufficient long term evidence.
The alopecia areata indication despite high unmet need remains a niche market with limited pricing power and the potential label may be restricted to severe to very severe patients which caps the addressable population. The willingness of dermatologists to adopt a new biologic for alopecia is uncertain given historical reluctance to prescribe systemic therapies due to monitoring requirements and the availability of off label topical agents. Even if approved the reimbursement path could be challenging and the commercial uptake slower than anticipated. Investors may be overestimating the speed of penetration in this indication.
Financial resources while strong are largely derived from recent equity financings that have diluted existing shareholders and could continue to do so if additional capital is needed for unexpected trial delays or expansion into further indications. The cash runway assumes on time enrollment and no major setbacks; any prolongation of the Phase 3 studies would burn cash faster than projected and could force a dilutive financing at less favorable terms. The balance sheet strength may therefore be temporary and contingent on successful execution.
The pipeline beyond ResPEG includes early stage TNFR2 programs that are still in preclinical phases and face the typical attrition rates of antibody therapeutics with no near term data catalysts to sustain investor interest. Reliance on a single late stage asset increases the binary nature of the investment where failure in either atopic dermatitis or alopecia areata could dramatically reduce enterprise value. The diversification argument may be premature given the lack of clinical proof of concept for the other programs.

The Phase 3 trials are still pending initiation and historical data show that moving from Phase 2b to Phase 3 often reveals unexpected safety signals or diminished efficacy especially when scaling to larger and more diverse patient populations. The reliance on a novel mechanism means there is limited long term safety data beyond the current exposure which could raise concerns among regulators and payers regarding chronic use. Any adverse event signal in the larger trials could jeopardize the BLA timeline and increase the need for additional studies. Investors may be overlooking the execution risk inherent in advancing a first in class immunomodulator to pivotal trials.
Although the company emphasizes a differentiated safety profile the JAK inhibitor class already faces boxed warnings and the introduction of a new biologic does not guarantee avoidance of safety signals particularly as the drug modulates regulatory T cells which could theoretically lead to immune suppression or paradoxical autoimmunity. The asthma improvement signal while promising also introduces complexity because demonstrating a benefit in a comorbid condition may require additional trials and could expand the safety monitoring burden. The market may be assuming safety advantages without sufficient long term evidence.
The alopecia areata indication despite high unmet need remains a niche market with limited pricing power and the potential label may be restricted to severe to very severe patients which caps the addressable population. The willingness of dermatologists to adopt a new biologic for alopecia is uncertain given historical reluctance to prescribe systemic therapies due to monitoring requirements and the availability of off label topical agents. Even if approved the reimbursement path could be challenging and the commercial uptake slower than anticipated. Investors may be overestimating the speed of penetration in this indication.
Financial resources while strong are largely derived from recent equity financings that have diluted existing shareholders and could continue to do so if additional capital is needed for unexpected trial delays or expansion into further indications. The cash runway assumes on time enrollment and no major setbacks; any prolongation of the Phase 3 studies would burn cash faster than projected and could force a dilutive financing at less favorable terms. The balance sheet strength may therefore be temporary and contingent on successful execution.
The pipeline beyond ResPEG includes early stage TNFR2 programs that are still in preclinical phases and face the typical attrition rates of antibody therapeutics with no near term data catalysts to sustain investor interest. Reliance on a single late stage asset increases the binary nature of the investment where failure in either atopic dermatitis or alopecia areata could dramatically reduce enterprise value. The diversification argument may be premature given the lack of clinical proof of concept for the other programs.

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password